Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI). Materials and methods: We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8). Results: We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1-positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1-negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1-positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1-positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment. Conclusion: Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.
Abstract
Purpose: This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI). Materials and methods: We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8). Results: We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1-positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1-negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1-positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1-positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment. Conclusion: Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.
참고문헌 (21)
- Witjes JA, "European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer : summary of the 2020 guidelines", Eur Urol, 79, pp.82~104 (2021)
- Patel VG, "Treatment of muscle-invasive and advanced bladder cancer in 2020", CA Cancer J Clin, 70, pp.404~423 (2020)
- Lawrence MS, "Mutational heterogeneity in cancer and the search for new cancer-associated genes", Nature, 499, pp.214~218 (2013)
- Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
- Aggen DH, "Biomarkers for immunotherapy in bladder cancer : a moving target", J Immunother Cancer, 5, pp.94~ (2017)
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of urothelial bladder carcinoma", Nature, 507, pp.315~322 (2014)
- Robertson AG, "Comprehensive molecular characterization of muscle-invasive bladder cancer", Cell, 171, pp.540~556 (2017)
- Kim ST, "Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer", Nat Med, 24, pp.1449~1458 (2018)
- Yarchoan M, "PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers", JCI Insight, 4, pp.e126908~ (2019)
- Lenis AT, "Bladder cancer : a review", JAMA, 324, pp.1980~1991 (2020)
- Gondkar K, "E74 like ETS transcription factor 3(ELF3)is a negative regulator of epithelial-mesenchymal transition in bladder carcinoma", Cancer Biomark, 25, pp.223~232 (2019)
- Gui Y, "Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder", Nat Genet, 43, pp.875~878 (2011)
- Tamborero D, "OncodriveCLUST : exploiting the positional clustering of somatic mutations to identify cancer genes", Bioinformatics, 29, pp.2238~2244 (2013)
- Sanchez-Vega F, "Oncogenic signaling pathways in the Cancer Genome Atlas", Cell, 173, pp.321~337 (2018)
- Alexandrov LB, "The repertoire of mutational signatures in human cancer", Nature, 578, pp.94~101 (2020)
- Powles T, "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma(DANUBE) : a randomised, open-label, multicentre, phase 3 trial", Lancet Oncol, 21, pp.1574~1588 (2020)
- van Dijk N, "Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer : the NABUCCO trial", Nat Med, 26, pp.1839~1844 (2020)
- Hedegaard J, "Comprehensive transcriptional analysis of early-stage urothelial carcinoma", Cancer Cell, 30, pp.27~42 (2016)
- Hurst CD, "Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency", Cancer Cell, 32, pp.701~715 (2017)
- Gajewski TF, "The next hurdle in cancer immunotherapy : overcoming the non-T-cell-inflamed tumor microenvironment", Semin Oncol, 42, pp.663~671 (2015)
- Sweis RF, "Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer", Cancer Immunol Res, 4, pp.563~568 (2016)